Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic antibodies for infectious diseases.
Sparrow E, Friede M, Sheikh M, Torvaldsen S. Sparrow E, et al. Bull World Health Organ. 2017 Mar 1;95(3):235-237. doi: 10.2471/BLT.16.178061. Epub 2017 Feb 2. Bull World Health Organ. 2017. PMID: 28250538 Free PMC article. No abstract available.
Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
Pitisuttithum P, Boonnak K, Chamnanchanunt S, Puthavathana P, Luvira V, Lerdsamran H, Kaewkungwal J, Lawpoolsri S, Thanachartwet V, Silachamroon U, Masamae W, Schuetz A, Wirachwong P, Thirapakpoomanunt S, Rudenko L, Sparrow E, Friede M, Kieny MP. Pitisuttithum P, et al. Among authors: sparrow e. Lancet Infect Dis. 2017 Aug;17(8):833-842. doi: 10.1016/S1473-3099(17)30240-2. Epub 2017 May 19. Lancet Infect Dis. 2017. PMID: 28533093 Free PMC article. Clinical Trial.
Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.
Rudenko L, Kiseleva I, Krutikova E, Stepanova E, Rekstin A, Donina S, Pisareva M, Grigorieva E, Kryshen K, Muzhikyan A, Makarova M, Sparrow EG, Torelli G, Kieny MP. Rudenko L, et al. Among authors: sparrow eg. PLoS One. 2018 Dec 3;13(12):e0208028. doi: 10.1371/journal.pone.0208028. eCollection 2018. PLoS One. 2018. PMID: 30507951 Free PMC article.
WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
Sparrow E, Adetifa I, Chaiyakunapruk N, Cherian T, Fell DB, Graham BS, Innis B, Kaslow DC, Karron RA, Nair H, Neuzil KM, Saha S, Smith PG, Srikantiah P, Were F, Zar HJ, Feikin D. Sparrow E, et al. Vaccine. 2022 Jun 9;40(26):3506-3510. doi: 10.1016/j.vaccine.2022.02.040. Epub 2022 Feb 17. Vaccine. 2022. PMID: 35184927 Free PMC article.
86 results